TY - JOUR T1 - Efficacy and safety of dupilumab in children aged 6鈥�11 years with inadequately controlled severe atopic dermatitis: Results from an open-label extension trial up to 1 year JO - Revue Fran莽aise d'Allergologie et d'Immunologie Clinique PY - 2022/04/01 AU - Cork MJ AU - Guttman-Yassky E AU - Simpson EL AU - Soong W AU - Wang Z AU - Chuang CC AU - O鈥檓alley JT AU - Bansal A ED - DO - DOI: 10.1016/j.reval.2022.02.078 VL - 62 IS - 3 SP - 321 Y2 - 2025/07/15 ER -